Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience

Published:2024-01-24 Issue:8 Volume:61 Page:793-800
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Lim Y. T.¹,Williams T. C.¹,Langley R. J.¹,Weir E.¹

Affiliation:

1. Department of Paediatric Respiratory, Royal Hospital for Children, Glasgow, UK

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2024.2303767

Reference32 articles.

1. Dupilumab (Dupixent). Scottish medicines consortium. 2021. https://www.scottishmedicines.org.uk/medicines-advice/dupilumab-dupixent-full-smc2317/

2. Dupilumab for treating severe asthma with type 2 inflammation: Guidance. NICE. 2021. https://www.nice.org.uk/guidance/ta751/chapter/1-Recommendations

3. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents;Sorkness CA;J Allergy Clin Immumol Pract,2013

4. Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study

5. Scottish Medicine Consortium 2016. Mepolizumab 100mg powder for solution for injection (NucalaVR). SMC No. (1149/16).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature;Children;2024-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP